Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Non Operating Income (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Non Operating Income for 6 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 58.09% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$331000.0 through Dec 2025, down 101.89% year-over-year, with the annual reading at -$331000.0 for FY2025, 101.89% down from the prior year.
  • Non Operating Income for Q4 2025 was $1.4 million at Caribou Biosciences, down from $1.9 million in the prior quarter.
  • The five-year high for Non Operating Income was $5.8 million in Q2 2024, with the low at -$6.5 million in Q2 2025.
  • Average Non Operating Income over 5 years is $2.0 million, with a median of $2.6 million recorded in 2021.
  • The sharpest move saw Non Operating Income tumbled 2940.96% in 2021, then surged 10931.25% in 2022.
  • Over 5 years, Non Operating Income stood at $2.2 million in 2021, then skyrocketed by 62.84% to $3.7 million in 2022, then dropped by 14.46% to $3.1 million in 2023, then rose by 7.86% to $3.4 million in 2024, then crashed by 58.09% to $1.4 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $1.4 million, $1.9 million, and -$6.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.